These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8790202)

  • 1. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
    Juweid ME; Sharkey RM; Behr T; Swayne LC; Dunn R; Siegel J; Goldenberg DM
    J Nucl Med; 1996 Sep; 37(9):1504-10. PubMed ID: 8790202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
    J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
    J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
    Wong JY; Williams LE; Yamauchi DM; Odom-Maryon T; Esteban JM; Neumaier M; Wu AM; Johnson DK; Primus FJ; Shively JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
    Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
    J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
    Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
    Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
    Hajjar G; Sharkey RM; Burton J; Zhang CH; Yeldell D; Matthies A; Alavi A; Losman MJ; Brenner A; Goldenberg DM
    Clin Colorectal Cancer; 2002 May; 2(1):31-42. PubMed ID: 12453334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
    J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.
    Buchegger F; Allal AS; Roth A; Papazyan JP; Dupertuis Y; Mirimanoff RO; Gillet M; Pelegrin A; Mach JP; Slosman DO
    Anticancer Res; 2000; 20(3B):1889-96. PubMed ID: 10928122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
    Richman CM; DeNardo SJ; O'Grady LF; DeNardo GL
    Cancer Res; 1995 Dec; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
    Kraeber-Bodéré F; Bardet S; Hoefnagel CA; Vieira MR; Vuillez JP; Murat A; Ferreira TC; Bardiès M; Ferrer L; Resche I; Gautherot E; Rouvier E; Barbet J; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3190s-3198s. PubMed ID: 10541363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.